What labs should be ordered for a patient presenting with peripheral neuropathy?

Laboratory Testing for Peripheral Neuropathy

Order a focused initial panel consisting of fasting blood glucose (or HbA1c), serum vitamin B12 with metabolites (methylmalonic acid and homocysteine), comprehensive metabolic panel, complete blood count, thyroid-stimulating hormone, and serum protein electrophoresis with immunofixation—these tests identify the vast majority of treatable causes. 1, 2, 3, 4, 5

Essential First-Line Laboratory Tests

The following tests have the highest diagnostic yield and should be ordered for all patients with peripheral neuropathy:

Diabetes Screening (Highest Yield)

• Fasting blood glucose or HbA1c is the single highest-yield test, as diabetes accounts for over 50% of peripheral neuropathy cases in Western populations and was elevated in approximately 11% of patients with distal symmetric polyneuropathy 1, 2, 5

Vitamin B12 Assessment

• Serum B12 with metabolites (methylmalonic acid ± homocysteine) is critical because standard B12 levels miss 44% of deficiency cases 1, 5
• Methylmalonic acid is more specific than homocysteine for B12 deficiency (elevated in 98.4% vs 95.9% of deficient patients) 1
• B12 deficiency was found in 2.2-8% of neuropathy patients, with metabolites detecting an additional 5-10% of cases when serum B12 was in the low-normal range (200-500 pg/dL) 1

Monoclonal Protein Screening

• Serum protein electrophoresis with immunofixation detects monoclonal gammopathies, which were abnormal in approximately 9% of patients with distal symmetric polyneuropathy 1, 4, 5

Additional Baseline Tests

• Complete blood count to assess for anemia, macrocytosis, or hematologic disorders 1, 3, 4
• Comprehensive metabolic panel (including creatinine/eGFR and liver function) to identify renal insufficiency and metabolic causes 1, 2, 3, 4
• Thyroid-stimulating hormone to exclude hypothyroidism 1, 3, 4
• Erythrocyte sedimentation rate for inflammatory conditions 1, 3

Clinical Context-Specific Testing

For Diabetic Patients

• Serum creatinine and eGFR are particularly important as renal insufficiency increases neuropathy risk and foot complication rates 2
• No additional laboratory tests beyond routine diabetes monitoring are needed if clinical findings are typical for diabetic neuropathy 6

When Atypical Features Are Present

Order additional tests only if the presentation is atypical (asymmetric distribution, rapid progression, motor predominance, or upper extremity involvement):

• Specialized antibody testing (anti-MAG antibodies if demyelinating sensory neuropathy; anti-GM1 if motor predominance) 1
• Hepatitis B, C, and HIV serology if risk factors present 1
• Heavy metal screening if exposure history suggests toxicity 6
• Genetic testing if family history or early onset suggests hereditary neuropathy 1

Tests with Low Diagnostic Yield

Cerebrospinal Fluid Analysis

• CSF analysis has low yield except in suspected demyelinating polyneuropathies (Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy), where elevated protein is expected 1, 3

Electrodiagnostic Studies

• Nerve conduction studies and EMG are not routine laboratory tests but are indicated when clinical examination cannot confirm the diagnosis or when differentiating axonal from demyelinating neuropathy is necessary 1, 6, 7, 8

Critical Clinical Distinctions

Laboratory tests do not diagnose diabetic peripheral neuropathy—clinical examination with the 10-g monofilament and 128-Hz tuning fork establishes the diagnosis. 6 Laboratory testing serves only to exclude alternative diagnoses in atypical cases 6

Common Pitfalls to Avoid

• Do not order extensive laboratory panels indiscriminately—laboratory tests alone have only 37% diagnostic yield without clinical context 1
• Do not skip B12 metabolites if serum B12 is low-normal (200-500 pg/dL), as this misses nearly half of deficiency cases 1
• Do not rely on homocysteine alone for B12 deficiency, as it is elevated in 91% of folate deficiency cases and lacks specificity 1
• Do not order nerve biopsy routinely—it is generally not indicated except in highly selected cases where diagnosis remains unclear after comprehensive evaluation 1, 7

Expected Diagnostic Yield

When combining clinical history, neurological examination, electrodiagnostic studies, and the recommended screening laboratory panel, an etiological diagnosis is established in 74-82% of peripheral neuropathy cases 1. The remaining 25-46% of cases are classified as idiopathic, though these patients generally have favorable prognosis 4, 7